Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mbIL21 NK-cell Infusions with HSCT for Pediatric Acute Leukemia
NCT07256210Phase 2Recruiting
- Sponsor
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
- Start
- May 2025
- Primary completion
- Oct 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of membrane-bound interleukin-21/4-1BB ligand-expanded natural killer cells in acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia (T-ALL) and mixed phenotype acute leukemia (MPAL), sponsored by Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Primary endpoint: Proportion of patients who received the planned dose of NK cells without adverse reactions grade ≥3 at 180 days. Started May 2025; status: recruiting.
02
Drugs
membrane-bound interleukin-21/4-1BB ligand-expanded natural killer cells
03
Conditions
acute myeloid leukemia (AML)T-cell acute lymphoblastic leukemia (T-ALL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT07256210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07256210.